JP2018515499A - Ｇｐｒ５５受容体の活性の選択的モジュレーター：クロメノピラゾール誘導体 - Google Patents

Ｇｐｒ５５受容体の活性の選択的モジュレーター：クロメノピラゾール誘導体 Download PDF

Info

Publication number
JP2018515499A
JP2018515499A JP2017557942A JP2017557942A JP2018515499A JP 2018515499 A JP2018515499 A JP 2018515499A JP 2017557942 A JP2017557942 A JP 2017557942A JP 2017557942 A JP2017557942 A JP 2017557942A JP 2018515499 A JP2018515499 A JP 2018515499A
Authority
JP
Japan
Prior art keywords
methoxy
pyrazole
dihydro
dimethylchromeno
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017557942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515499A5 (https=
Inventor
ハヘロヴィク，ナディン
ラザロ，パウラ モラレス
ラザロ，パウラ モラレス
ロス，ルース
ホワイト，ローレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Original Assignee
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto filed Critical University of Toronto
Publication of JP2018515499A publication Critical patent/JP2018515499A/ja
Publication of JP2018515499A5 publication Critical patent/JP2018515499A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017557942A 2015-05-05 2016-04-27 Ｇｐｒ５５受容体の活性の選択的モジュレーター：クロメノピラゾール誘導体 Pending JP2018515499A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201530608A ES2593057B1 (es) 2015-05-05 2015-05-05 Moduladores selectivos de la actividad del receptor GPR55: derivados de cromenopirazol
ESP201530608 2015-05-05
PCT/ES2016/070314 WO2016177922A1 (es) 2015-05-05 2016-04-27 Moduladores selectivos de la actividad del receptor gpr55: derivados de cromenopirazol

Publications (2)

Publication Number Publication Date
JP2018515499A true JP2018515499A (ja) 2018-06-14
JP2018515499A5 JP2018515499A5 (https=) 2019-06-06

Family

ID=57217626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017557942A Pending JP2018515499A (ja) 2015-05-05 2016-04-27 Ｇｐｒ５５受容体の活性の選択的モジュレーター：クロメノピラゾール誘導体

Country Status (13)

Country Link
US (1) US10435412B2 (https=)
EP (1) EP3305794B1 (https=)
JP (1) JP2018515499A (https=)
KR (1) KR20180002717A (https=)
CN (1) CN107735397A (https=)
AU (1) AU2016257025A1 (https=)
BR (1) BR112017023834A2 (https=)
CA (1) CA2985021A1 (https=)
ES (1) ES2593057B1 (https=)
IL (1) IL255420A0 (https=)
MX (1) MX2017014145A (https=)
RU (1) RU2017138563A (https=)
WO (1) WO2016177922A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109420174B (zh) * 2017-08-31 2021-07-13 清华大学 Gpr18及其调节剂在防治免疫系统疾病中的应用
CN109420173B (zh) * 2017-08-31 2021-07-13 清华大学 Gpr55及其调节剂在防治免疫系统疾病中的应用
EP4472947A1 (en) * 2022-03-07 2024-12-11 Firmenich Incorporated Sweetener compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074844A1 (en) * 2003-02-18 2004-09-02 Astrazeneca Ab Screening assays for cannabinoid-ligand-type modulators of gpr55
JP2010514810A (ja) * 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
WO2010109050A1 (es) * 2009-03-24 2010-09-30 Consejo Superior De Investigaciones Científicas (Csic) Derivados de cromenopirazoles como ligandos de receptores de cannabinoides
WO2014013117A1 (es) * 2012-07-18 2014-01-23 Consejo Superior De Investigaciones Científicas (Csic) Cromenopirazoldionas como derivados cannabinoides de quinonas con actividad antitumoral

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624102A (en) * 1969-05-21 1971-11-30 Warner Lambert Co Substituted benzopyranopyrazoles
GB0010960D0 (en) 2000-05-05 2000-06-28 Glaxo Group Ltd Assay
WO2009010824A1 (en) * 2007-07-13 2009-01-22 Glenmark Pharmaceuticals, S.A. Dihydrochromenopyrazole derivatives as vanilloid receptor ligands
ES2548789B1 (es) 2014-03-18 2016-08-08 Consejo Superior De Investigaciones Científicas (Csic) Nuevas cromenoquinonas moduladoras de receptores cannabinoidescb2 con actividad antitumoral

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074844A1 (en) * 2003-02-18 2004-09-02 Astrazeneca Ab Screening assays for cannabinoid-ligand-type modulators of gpr55
JP2010514810A (ja) * 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
WO2010109050A1 (es) * 2009-03-24 2010-09-30 Consejo Superior De Investigaciones Científicas (Csic) Derivados de cromenopirazoles como ligandos de receptores de cannabinoides
WO2014013117A1 (es) * 2012-07-18 2014-01-23 Consejo Superior De Investigaciones Científicas (Csic) Cromenopirazoldionas como derivados cannabinoides de quinonas con actividad antitumoral

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CUMELLA, J. ET AL.: "Chromenopyrazoles: Non-psychoactive and Selective CB1 Cannabinoid Agonists with Peripheral Antinocic", CHEMMEDCHEM, vol. 7(3), JPN6020017451, 2012, pages 452 - 463, ISSN: 0004271513 *

Also Published As

Publication number Publication date
US20180201620A1 (en) 2018-07-19
EP3305794A1 (en) 2018-04-11
ES2593057A1 (es) 2016-12-05
AU2016257025A1 (en) 2017-11-30
WO2016177922A1 (es) 2016-11-10
EP3305794B1 (en) 2020-02-05
EP3305794A4 (en) 2018-11-07
IL255420A0 (en) 2017-12-31
RU2017138563A3 (https=) 2019-06-06
BR112017023834A2 (pt) 2018-07-31
MX2017014145A (es) 2018-06-20
CA2985021A1 (en) 2016-11-10
KR20180002717A (ko) 2018-01-08
RU2017138563A (ru) 2019-06-05
ES2593057B1 (es) 2017-09-12
US10435412B2 (en) 2019-10-08
CN107735397A (zh) 2018-02-23

Similar Documents

Publication Publication Date Title
EP3204359B1 (en) Tetrahydroisoquinoline derivatives
JP2021006554A (ja) ＮＲ２ＢのＮ−アルキルアリール−５−オキシアリール−オクタヒドロ−シクロペンタ［ｃ］ピロールネガティブアロステリックモジュレーター
TWI818985B (zh) 作為類視色素相關孤兒受體γ（ＲＯＲγ）調節劑之苯并咪唑衍生物及其醫藥用途
CA2765678A1 (en) Substituted hydroxamic acids and uses thereof
JP2007525482A (ja) イオンチャネルリガンドとしてのアミド化合物およびその使用
SK278553B6 (en) Azaheterocyclymethyl-chromates, manufacturing process thereof and pharmaceutical composition containing same
JP5155864B2 (ja) ５−ＨＴ２Ｃ受容体アゴニストとしての６−アリールアルキルアミノ−２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
CN102933574A (zh) (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
US10106523B2 (en) Amide compound
WO2017081483A1 (en) Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors
JP2021191753A (ja) 疾患の処置のための複素環化合物
CN115703761A (zh) 作为wwp1抑制剂的化合物及其应用
JP2018515499A (ja) Ｇｐｒ５５受容体の活性の選択的モジュレーター：クロメノピラゾール誘導体
CN117362231A (zh) 一种取代脒类化合物的合成方法及其用途
EP2896613B1 (en) Sulfonamide compound
JP2022537330A (ja) インダゾール誘導体、その製造方法及び医薬上のその使用
CZ281714B6 (cs) Piperidylmethylsubstituované deriváty chromanu
CN107501270B (zh) 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用
CN115141153B (zh) 一种苯并二氮杂䓬类化合物及其制备方法与应用
WO2018206820A1 (en) Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
AU2008330653A1 (en) Fused indane compound
CN119143734A (zh) 作为at2r拮抗剂的杂环化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201221